Logo image of RLMD

RELMADA THERAPEUTICS INC (RLMD) Stock Fundamental Analysis

USA - NASDAQ:RLMD - US75955J4022 - Common Stock

3.95 USD
+0.07 (+1.8%)
Last: 11/14/2025, 8:23:33 PM
Fundamental Rating

2

Overall RLMD gets a fundamental rating of 2 out of 10. We evaluated RLMD against 192 industry peers in the Pharmaceuticals industry. The financial health of RLMD is average, but there are quite some concerns on its profitability. RLMD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RLMD has reported negative net income.
RLMD had a negative operating cash flow in the past year.
In the past 5 years RLMD always reported negative net income.
RLMD had a negative operating cash flow in each of the past 5 years.
RLMD Yearly Net Income VS EBIT VS OCF VS FCFRLMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

RLMD has a worse Return On Assets (-322.42%) than 93.23% of its industry peers.
RLMD has a worse Return On Equity (-426.87%) than 77.60% of its industry peers.
Industry RankSector Rank
ROA -322.42%
ROE -426.87%
ROIC N/A
ROA(3y)-126.18%
ROA(5y)-97.03%
ROE(3y)-150.91%
ROE(5y)-113.88%
ROIC(3y)N/A
ROIC(5y)N/A
RLMD Yearly ROA, ROE, ROICRLMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

RLMD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RLMD Yearly Profit, Operating, Gross MarginsRLMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

RLMD has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RLMD has more shares outstanding
RLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RLMD Yearly Shares OutstandingRLMD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
RLMD Yearly Total Debt VS Total AssetsRLMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

RLMD has an Altman-Z score of -39.20. This is a bad value and indicates that RLMD is not financially healthy and even has some risk of bankruptcy.
RLMD's Altman-Z score of -39.20 is on the low side compared to the rest of the industry. RLMD is outperformed by 89.58% of its industry peers.
RLMD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -39.2
ROIC/WACCN/A
WACCN/A
RLMD Yearly LT Debt VS Equity VS FCFRLMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

RLMD has a Current Ratio of 4.11. This indicates that RLMD is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of RLMD (4.11) is better than 63.02% of its industry peers.
A Quick Ratio of 4.11 indicates that RLMD has no problem at all paying its short term obligations.
RLMD's Quick ratio of 4.11 is fine compared to the rest of the industry. RLMD outperforms 64.58% of its industry peers.
Industry RankSector Rank
Current Ratio 4.11
Quick Ratio 4.11
RLMD Yearly Current Assets VS Current LiabilitesRLMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

RLMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 37.28%, which is quite impressive.
EPS 1Y (TTM)37.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RLMD will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.59% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.71%
EPS Next 2Y16%
EPS Next 3Y12.16%
EPS Next 5Y11.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RLMD Yearly EPS VS EstimatesRLMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RLMD. In the last year negative earnings were reported.
Also next year RLMD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RLMD Price Earnings VS Forward Price EarningsRLMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RLMD Per share dataRLMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as RLMD's earnings are expected to grow with 12.16% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16%
EPS Next 3Y12.16%

More info and screens

0

5. Dividend

5.1 Amount

RLMD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RELMADA THERAPEUTICS INC

NASDAQ:RLMD (11/14/2025, 8:23:33 PM)

3.95

+0.07 (+1.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2025-11-13/amc
Earnings (Next)03-25 2026-03-25/amc
Inst Owners34.34%
Inst Owner Change44.76%
Ins Owners11.66%
Ins Owner Change53.48%
Market Cap131.10M
Revenue(TTM)N/A
Net Income(TTM)-68.08M
Analysts45.71
Price Target1.02 (-74.18%)
Short Float %2.14%
Short Ratio0.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-50.54%
Min EPS beat(2)-83.43%
Max EPS beat(2)-17.65%
EPS beat(4)1
Avg EPS beat(4)-24.55%
Min EPS beat(4)-83.43%
Max EPS beat(4)12.98%
EPS beat(8)5
Avg EPS beat(8)-3.61%
EPS beat(12)8
Avg EPS beat(12)-0.78%
EPS beat(16)9
Avg EPS beat(16)-4.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)15.38%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 8.22
P/tB 8.22
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.73
Fwd EYN/A
FCF(TTM)-1.51
FCFYN/A
OCF(TTM)-1.51
OCFYN/A
SpS0
BVpS0.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -322.42%
ROE -426.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-126.18%
ROA(5y)-97.03%
ROE(3y)-150.91%
ROE(5y)-113.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.11
Quick Ratio 4.11
Altman-Z -39.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)37.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%58.33%
EPS Next Y25.71%
EPS Next 2Y16%
EPS Next 3Y12.16%
EPS Next 5Y11.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y22.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-17.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y45.71%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.71%
OCF growth 3YN/A
OCF growth 5YN/A

RELMADA THERAPEUTICS INC / RLMD FAQ

What is the ChartMill fundamental rating of RELMADA THERAPEUTICS INC (RLMD) stock?

ChartMill assigns a fundamental rating of 2 / 10 to RLMD.


What is the valuation status of RELMADA THERAPEUTICS INC (RLMD) stock?

ChartMill assigns a valuation rating of 0 / 10 to RELMADA THERAPEUTICS INC (RLMD). This can be considered as Overvalued.


How profitable is RELMADA THERAPEUTICS INC (RLMD) stock?

RELMADA THERAPEUTICS INC (RLMD) has a profitability rating of 0 / 10.


What is the earnings growth outlook for RELMADA THERAPEUTICS INC?

The Earnings per Share (EPS) of RELMADA THERAPEUTICS INC (RLMD) is expected to grow by 25.71% in the next year.